GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » Operating Cash Flow per Share

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Operating Cash Flow per Share : $-6.88 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals Operating Cash Flow per Share?

Quoin Pharmaceuticals's operating cash flow per share for the three months ended in Mar. 2024 was $-0.68. Quoin Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.88.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 28.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Quoin Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

QNRX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -21.9   Med: 3.3   Max: 28.5
Current: 28.5

During the past 5 years, Quoin Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 28.50% per year. The lowest was -21.90% per year. And the median was 3.30% per year.

QNRX's 3-Year OCF Growth Rate is ranked better than
77.8% of 1234 companies
in the Biotechnology industry
Industry Median: 3.35 vs QNRX: 28.50

Quoin Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Quoin Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals Operating Cash Flow per Share Chart

Quoin Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
-23.20 -23.91 -220.00 -41.99 -8.73

Quoin Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -1.59 -1.34 -3.26 -0.68

Competitive Comparison of Quoin Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Quoin Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quoin Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



Quoin Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Quoin Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-7.864/0.901
=-8.73

Quoin Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-1.434/2.103
=-0.68

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quoin Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Executives
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper director PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell director C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn officer: Chief Financial Officer AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter director, officer: Chief Operating Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers director, officer: Chief Executive Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Headlines

From GuruFocus